Potential Benefits

• Weight Loss
• Feeling Better Satisfied On A Diet

Cagrilintide is a once-weekly treatment developed by Novo Nordisk for chronic weight management, either as monotherapy or combined with other GLP-1 treatments. It works by activating receptors in the brainstem that govern satiety, meal size, and gastric emptying.

In clinical trials, cagrilintide monotherapy produced an average weight reduction of 11.8% versus 2.3% with placebo over 68 weeks. When paired with semaglutide, participants achieved 22.7% mean weight loss, more than either individual treatment alone.

Substantial, Clinical Meaningful Weight Loss

When combined with semaglutide, weight loss approached outcomes historically seen only with bariatric surgery

Appetite Regulating

Cagrilintide’s half-life is roughly 160 hours, which means it can help control hunger urges and help patients feel more satisfied on a diet.

No Bone Density Loss

Cagrilintide treatment showed no significant change in bone density over 68 weeks.

Considerations

Once weekly dosage. As of 2026, cagrilintide remains investigational, with development focused on the combination with semaglutide. Novo Nordisk has filed for regulatory approval, though timing is unannounced. It is generally well tolerated, with side effects similar to semaglutide. It should only be used under supervision.

Book a FREE In-Person Peptide Therapy Consultation in Grand Blanc:

To determine if Cagrilintide could be right for you, schedule a consultation with our Beauti Pharm staff. Click the Schedule Consultation button below, scroll to “Peptide Therapy”, click, then click on “Peptide Therapy Consultation In-Person” and follow the prompts! During your consultation, we will perform an evaluation and review options so you can make the best decision for your personal wellness and performance goals.